PhD student Annelien Morlion presents her recent work on plasma cell-free RNA profiles in cancer type and patient-specific changes.
Background: Circulating nucleic acids in blood plasma form an attractive resource to study human health and disease. While the presence of extracellular RNAs in plasma has been firmly established, their origin and clinical utility for management of cancer patients is less understood.
Methods: In this study, we applied messenger RNA capture sequencing of blood plasma cell-free RNA from 266 cancer patients and cancer-free controls (discovery n=208, 25 cancer types; validation n=58, 3 types).
Post-doctoral fellow Anneleen Decock presents her recent work on reporting pre-analytical variables in RNA-focused blood plasma studies.
Background: Blood-derived liquid biopsies are appealing biomaterials for various purposes in many medical disciplines as they offer a wide spectrum of analytes to be studied, including extracellular RNA (cell-free RNA; exRNA). The outcome of exRNA measurements is greatly influenced by pre-analytical variables, stressing the importance of disclosing pre-analytic variables in publications to enable adequate interpretation and comparison of research results.
Doctoral researcher Annelien Morlion presented her work on changes in blood plasma cell-free RNA profiles of cancer patients and how heterogeneity can be exploited for cancer classification
Doctoral researcher Jill Deleu presented her work on the development of a host-xenograft deconvolution framework, exRNAxeno, with mapping strategies to either a combined human-mouse reference genome or both species genomes in parallel, applicable to exRNA sequencing data from liquid biopsies of human xenograft mouse models
Doctoral researcher Hanne Van Droogenbroeck presented her work were she investigated which factors influence the exRNA shedding of tumor into blood plasma
Doctoral researcher Jill Deleu presented her work were she evaluated whether circulating miRNAs are suitable to monitor neuroblastoma tumour burden and whether treatment-induced changes of miRNA abundance in the tumour are detectable in serum